Ohm Oncology Competitors and Similar CompaniesClear all
Ohm Oncology's competitors and similar companies include Blueprint Medicines, Achilles Therapeutics, BeOne Medicines and Marker Therapeutics.
 Ohm Oncology Ohm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds. |  Blueprint Medicines Blueprint Medicines is a biopharmaceutical company engaged in developing therapies for allergy, inflammation, and oncology/hematology. |  Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. |  BeOne Medicines BeOne Medicines (formerly known as BeiGene) is a biotechnology company that discovers and develops oncology cancer treatments. |  Marker Therapeutics Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. | |
Founding Date | Founding Date 2015 | Founding Date 2011 | Founding Date 2016 | Founding Date 2010 | Founding Date 2018 |
Type | Type Private | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Austin, US HQ | Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH | Locations London, GB HQ Stevenage, GB | Locations Houston, US HQ | |
Employees | Employees 167% decrease | Employees 6552% increase | Employees 695% decrease | Employees 12,0009% increase | Employees 888% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 5.3 b | Valuation ($) N/A | Valuation ($) 23.8 b | Valuation ($) 36.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $508.8m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $5.3b (FY, 2025) | Revenue (est.) $3.5m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $20.2m (FY, 2024) | Cost of goods N/A | Cost of goods $668.5m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $488.7m (FY, 2024) | Gross profit N/A | Gross profit $4.7b (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income ($67.1m) (FY, 2024) | Net income ($69.7m) (FY, 2023) | Net income $286.9m (FY, 2025) | Net income ($12.2m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 1.7b | Total funding raised $ 138.1m | Total funding raised $ 75m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Blueprint Medicines
HQ
Cambridge, US
Employees
655↑ 2% increase
Blueprint Medicines is a biopharmaceutical company engaged in developing therapies for allergy, inflammation, and oncology/hematology.
View companyAchilles Therapeutics
HQ
London, GB
Employees
69↓ 5% decrease
Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.
View companyBeOne Medicines
HQ
Cambridge, US
Employees
12,000↑ 9% increase
BeOne Medicines (formerly known as BeiGene) is a biotechnology company that discovers and develops oncology cancer treatments.
View companyMarker Therapeutics
HQ
Houston, US
Employees
8
Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection.
View company